Kymera Therapeutics Stock Analysis
| KYMR Stock | USD 33.70 1.16 3.56% |
Kymera Therapeutics is undervalued with Real Value of 38.99 and Hype Value of 33.53. The main objective of Kymera Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Kymera Therapeutics is worth, separate from its market price. There are two main types of Kymera Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Kymera Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Kymera Therapeutics is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Kymera Stock trading window is adjusted to America/New York timezone.
Kymera |
Kymera Stock Analysis Notes
About 98.0% of the company shares are owned by institutional investors. The book value of Kymera Therapeutics was now reported as 12.88. The company has Price/Earnings To Growth (PEG) ratio of 0.64. Kymera Therapeutics recorded a loss per share of 2.98. The entity had not issued any dividends in recent years. Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the bodys own natural protein degradation system. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts. Kymera Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 160 people. To find out more about Kymera Therapeutics contact the company at 857 285 5300 or learn more at https://www.kymeratx.com.Kymera Therapeutics Investment Alerts
| Kymera Therapeutics generated a negative expected return over the last 90 days | |
| Kymera Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 47.07 M. Net Loss for the year was (223.86 M) with loss before overhead, payroll, taxes, and interest of (193.18 M). | |
| Kymera Therapeutics currently holds about 392.31 M in cash with (194.5 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.61. | |
| Over 98.0% of the company shares are owned by institutional investors |
Kymera Therapeutics Upcoming and Recent Events
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Kymera Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.11 B.Technical Drivers
As of the 24th of March, Kymera Therapeutics secures the Risk Adjusted Performance of (0.05), standard deviation of 3.84, and Mean Deviation of 2.85. Kymera Therapeutics technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices. Please verify Kymera Therapeutics variance and skewness to decide if Kymera Therapeutics is priced some-what accurately, providing market reflects its recent price of 33.7 per share. Given that Kymera Therapeutics has information ratio of (0.06), we recommend you to check Kymera Therapeutics's last-minute market performance to make sure the company can sustain itself at a future point.Kymera Therapeutics Price Movement Analysis
java.lang.NullPointerException: Cannot invoke "java.lang.Number.intValue()" because the return value of "sun.invoke.util.ValueConversions.primitiveConversion(sun.invoke.util.Wrapper, Object, boolean)" is null. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Kymera Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Kymera Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Kymera Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Kymera Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Kymera Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Kymera Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Kymera Therapeutics Outstanding Bonds
Kymera Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Kymera Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Kymera bonds can be classified according to their maturity, which is the date when Kymera Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Kymera Therapeutics Predictive Daily Indicators
Kymera Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Kymera Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 28338.1 | |||
| Daily Balance Of Power | 0.4833 | |||
| Rate Of Daily Change | 1.04 | |||
| Day Median Price | 34.08 | |||
| Day Typical Price | 33.95 | |||
| Price Action Indicator | 0.2 | |||
| Period Momentum Indicator | 1.16 |
Kymera Therapeutics Forecast Models
Kymera Therapeutics' time-series forecasting models are one of many Kymera Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Kymera Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Kymera Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Kymera Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Kymera shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Kymera Therapeutics. By using and applying Kymera Stock analysis, traders can create a robust methodology for identifying Kymera entry and exit points for their positions.
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the bodys own natural protein degradation system. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts. Kymera Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 160 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Kymera Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Theme Ratings Now
Theme RatingsDetermine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |
| All Next | Launch Module |
Additional Tools for Kymera Stock Analysis
When running Kymera Therapeutics' price analysis, check to measure Kymera Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kymera Therapeutics is operating at the current time. Most of Kymera Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kymera Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kymera Therapeutics' price. Additionally, you may evaluate how the addition of Kymera Therapeutics to your portfolios can decrease your overall portfolio volatility.